Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.

PET/CT follicular lymphoma maintenance therapy metabolic tumor volume prognostication

Journal

Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Titre abrégé: Ann Oncol
Pays: England
ID NLM: 9007735

Informations de publication

Date de publication:
28 Oct 2023
Historique:
received: 15 07 2023
revised: 22 09 2023
accepted: 13 10 2023
pubmed: 29 10 2023
medline: 29 10 2023
entrez: 28 10 2023
Statut: aheadofprint

Résumé

We investigated the prognostic value of baseline positron emission tomography (PET) parameters for patients with treatment-naïve follicular lymphoma (FL) in the phase III RELEVANCE trial, comparing the immunomodulatory combination of lenalidomide and rituximab (R Baseline characteristics of the entire PET-evaluable population (n = 406/1032) were well balanced between treatment arms. The maximal standard uptake value (SUV With a median follow-up of 6.5 years, the 6-year progression-free survival (PFS) was 57.8%, the median TMTV was 284 cm Baseline TMTV is predictive of PFS, independently of FLIPI, in patients with advanced FL even in the context of antibody maintenance.

Sections du résumé

BACKGROUND BACKGROUND
We investigated the prognostic value of baseline positron emission tomography (PET) parameters for patients with treatment-naïve follicular lymphoma (FL) in the phase III RELEVANCE trial, comparing the immunomodulatory combination of lenalidomide and rituximab (R
PATIENTS AND METHODS METHODS
Baseline characteristics of the entire PET-evaluable population (n = 406/1032) were well balanced between treatment arms. The maximal standard uptake value (SUV
RESULTS RESULTS
With a median follow-up of 6.5 years, the 6-year progression-free survival (PFS) was 57.8%, the median TMTV was 284 cm
CONCLUSIONS CONCLUSIONS
Baseline TMTV is predictive of PFS, independently of FLIPI, in patients with advanced FL even in the context of antibody maintenance.

Identifiants

DOI: 10.1016/j.annonc.2023.10.121 PMID: 37898239
pubmed: 37898239
pii: S0923-7534(23)04327-2
doi: 10.1016/j.annonc.2023.10.121
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2023 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.

Auteurs

A S Cottereau (AS)

Department of Nuclear Medicine, Cochin Hospital, AP-HP, Université Paris Cité, Paris. Electronic address: annesegolene.cottereau@aphp.fr.

L Rebaud (L)

LITO Laboratory, UMR 1288 Inserm, Institut Curie, Université Paris-Saclay, Orsay; Siemens Healthcare SAS, Saint Denis, France.

J Trotman (J)

Department of Hematology, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.

P Feugier (P)

Department of Hematology, University Hospital of Nancy and INSERM 1256 University of Lorraine, Vandœuvre-lès-Nancy, France.

L J Nastoupil (LJ)

Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, USA.

E Bachy (E)

EA LIB (Lymphoma Immuno-Biology), University Claude Bernard Lyon 1, Lyon, France.

I W Flinn (IW)

Sarah Cannon Research Institute/Tennessee Oncology, Nashville, USA.

C Haioun (C)

Lymphoïd Malignancies Unit, Henri Mondor Hospital, AP-HP, Créteil.

L Ysebaert (L)

Department of Hematology, IUC Toulouse-Oncopole Toulouse, Toulouse, France.

N L Bartlett (NL)

Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA.

H Tilly (H)

Imaging Department, Centre Henri Becquerel, Rouen; QuantIF-LITIS, EA 4108, IRIB, University of Rouen, Rouen.

O Casasnovas (O)

Department of Hematology, F Mitterrand Hospital, Dijon; Inserm 1231, University of Dijon.

R Ricci (R)

LYSARC, Centre Hospitalier Lyon-Sud, Pierre-Bénite.

C Portugues (C)

LYSARC, Centre Hospitalier Lyon-Sud, Pierre-Bénite.

I Buvat (I)

LITO Laboratory, UMR 1288 Inserm, Institut Curie, Université Paris-Saclay, Orsay.

M Meignan (M)

Lysa Imaging, Henri Mondor University Hospital, AP-HP, University Paris East, Creteil.

F Morschhauser (F)

Department of Hematology, University of Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, France.

Classifications MeSH